Study of LY2157299 in Japanese Participants With Cancer
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in Japanese participants with advanced cancer or cancer that has spread to other parts of the body.
Neoplasms|Neoplasm Metastasis
DRUG: LY2157299
Number of Participants with Dose-Limiting Toxicities, Day 1 through Day 28 of Cycle 1
Pharmacokinetics: Maximum Concentration (Cmax) of LY2157299, Days 1, 3, 6 and 14 of Cycle 1 and Days 1 and 14 of Cycle 2|Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY2157299, Predose up to 6 hours postdose on Days 1 and 14 of Cycles 1 and 2|Number of Participants with a Tumor Response, Baseline to study completion estimated at 16 weeks
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in Japanese participants with advanced cancer or cancer that has spread to other parts of the body.